The world’s first four-dimensional visual insight into the residual effects of COVID-19 or “long COVID” providing an unprecedented ability for patients, clinicians and researchers to understand the continued impact of this disease was obtained at the using 4DMedical’s unique XV technology.
4DMedical today confirmed that patients with COVID have been scanned as part of a comprehensive program of pilot clinical studies conducted in Melbourne, validating the application of this breakthrough technology in the detection and diagnosis of various respiratory conditions , and providing longer-term secure monitoring and surveillance. the impact of diseases, including COVID-19.
This XV technology developed in Australia provides much more insight into the residual physiological effects of COVID-19 than can be obtained using established imaging methods and pulmonary function tests which may not detect evidence. of this prevalent condition.
“Using XV technology, doctors can detect areas of high and low ventilation with pinpoint accuracy in all parts of the lung, in all phases of breathing,” said Dr Ray Casciari, a pulmonologist with extensive experience in interpretation of four-dimensional scans, based at St Joseph’s Hospital in Orange, California.
“The resulting ventilation report provides clinicians with a dynamic, color-coded visualization of the patient’s lung, enhanced with four-dimensional animation,” added Dr. Casciari. “This report is extremely clear and easy to understand, and I can use it to inform my own analysis and show the effect of COVID on the patient. “
“So far, much of the attention to COVID has been focused on the epidemiology of its spread, and more recently on the effect of vaccines,” said Dr Andreas Fouras, CEO of 4DMedical. “Health authorities are increasingly focusing on how to assess, understand and manage the lingering effects of COVID on people who have been affected by the disease. “
More than 166 million people around the world have endured and recovered from COVID. The potential of 4DMedical’s XV technology to play a role in monitoring residual effects is unprecedented, as is our ability to monitor the effectiveness of pharmaceutical and other interventions for the treatment of these residual effects of COVID. Patients and their doctors had never been able to see lungs with this level of richness and detail before. “
Dr Andreas Fouras, Managing Director, 4DMedical
“Long COVID” is a range of symptoms that can last for weeks or months after infection and can impact people with mild or even asymptomatic reactions to the disease.
Experts continue to learn more about the short and long term effects of COVID-19, who is affected and what form the residual effects take. Breakthrough in respiratory imaging announced today allows research to advance faster and, for individual cases, to be more closely monitored using advanced technology in treatment and studies. larger clinics.